Drug abuse is a global problem of considerable concern to health. One such health concern stems from the fact that many drugs of abuse have immunosuppressive actions, and consequently have the potential to increase susceptibility to infectious disease. This article is focused on the impact of the amphetamine derivative methylenedioxymethamphetamine (MDMA; "Ecstasy") on immunity. Research conducted over the last five years has demonstrated that MDMA has immunosuppressive actions, in both laboratory animals and humans. Specifically, MDMA suppress neutrophil phagocytosis, suppresses production of the pro-inflammatory cytokines TNF- and IL-1 and increases production of an endogenous immunosuppressive cytokine IL-10, thereby promoting an immunosuppressive cytokine phenotype. MDMA also suppresses circulating lymphocyte numbers, with CD4 + T-cells being particularly affected, and alters T-cell function as indicated by reduced mitogen stimulated Tcell proliferation, and a skewing of T-cell cytokine production in a Th 2 direction. For the most part the aforementioned effects of MDMA are not due to a direct action of the drug on immune cells, but rather due to the release of endogenous immunomodulatory substances.
Introduction
Drug abuse is a worldwide problem that has major social, health and economic implications.
Over the last two decades investigators have documented the ability of a number of drugs of abuse such as cocaine, opioids, cannabinoids and amphetamines to impair many aspects of immune function, either directly, or via neuroimmune pathways [1] [2] [3] [4] [5] [6] . In addition, there is substantial evidence that the stress associated with morphine and cocaine withdrawal also induces an immunosuppressive state [7, 8] . Moreover, numerous reports indicate that the immunosuppression elicited by drugs of abuse can result in diminished host resistance to disease in a number of experimental models [9] [10] [11] [12] . Indeed some investigators have implicated drug abuse as a co-factor in susceptibility to infection with HIV or other viruses [10, 11, 13, 14] .
This review focuses on the immunomodulatory capacity of methylenedioxymethamphetamine (MDMA; "Ecstasy"), an amphetamine-derivative that has become a popular drug of abuse over the last two decades [15, 16] .
MDMA -History and biological actions
MDMA is a ring-substituted phenylisopropylamine that is structurally related to both amphetamines and hallucinogens. The compound was initially developed as an appetite suppressant in 1914 by Merck Pharmaceuticals, but was never marketed for this purpose. It was later discovered that MDMA had psychoactive properties, and it was reported to confer benefit as an adjunct to psychotherapy, where it was shown to enhance communication and intimacy [16] . In the 1980's MDMA became a popular drug of abuse, particularly at raves and all night dance clubs. However, following an increase in the prevalence of it's abuse, and In terms of its neurochemical mechanism of action, MDMA is a potent releaser of the indolamine neurotransmitter serotonin, and to a lesser extent the catecholamine neurotransmitter dopamine in the central nervous system (CNS) [17, 18] . These neurochemical actions of MDMA result in psychoactive properties that have been studied both in animals and humans [19] [20] [21] . In humans, MDMA produces a relaxed, euphoric state, including emotional openness, increased empathy and a decrease in inhibitions. These subjective behavioural effects elicited by MDMA have led to its widespread abuse over the last [15] [16] [17] [18] [19] [20] . Experimental studies conducted in laboratory animals [22, 23] and humans [21] have concluded that many of these actions of MDMA occur secondary to central release of either serotonin or dopamine.
MDMA use has been associated with a number of serious side effects, such as cardiac arrhythmias, hyperthermia, renal failure, seizures and intracranial hemorrhage [see 15, 16] . In addition, to these acute toxic effects there is substantial evidence that MDMA can result in long-term neurotoxic effects on central serotonergic neurons [24, 25] , and that this may represent a predisposing factor to psychological disturbances/psychiatric disease [see 26].
In the last number of years it has become evident that, like other drugs of abuse, MDMA has immunosuppressive properties. A number of studies indicate that MDMA suppresses aspects of both innate and adaptive immunity in laboratory animals [27] [28] [29] [30] [31] [32] [33] [34] and in humans [35] [36] [37] [38] [39] . In the remainder of this review I will discuss the evidence that MDMA impacts upon immune function, discuss the potential mechanisms by which MDMA elicits it's immunomodulatory actions, and also discuss the potential of MDMA-induced immunosuppression to translate into significant health risks for abusers. In vivo effects of MDMA in animal models
Innate immunity
Neutrophils are a subset of phagocytic cells that play a key role in the innate immune response.
Neutrophil activation that occurs following phagocytosis is accompanied by an oxidative burst that produces reactive oxygen species, and destroys bacteria and fungi. Administration of MDMA (10 mg/kg) to rats has been shown to suppress the neutrophil oxidative burst in response to opsonised zymosan (a phagocytic stimulus), but not in response to chemical stimulation of protein kinase C using the phorbol ester PMA [27] . The fact that the PMA- MDMA administration to rats impairs the ability to respond to an in vivo immune challenge with bacterial lipopolysaccharide (LPS). Specifically, MDMA suppresses LPS-induced IL-1
and TNF- production [28, 30, 31] . In addition, to producing pro-inflammatory cytokines, cells of the innate immune system also produce interleukin-10 (IL-10), an anti-inflammatory or immunosuppressive cytokine that inhibits several macrophage functions including pro-inflammatory cytokine production in response to lipopolysaccharide [44] [45] [46] [47] . In a recent study it was demonstrated that MDMA provokes a dose-dependent increase in IL-10 following an in vivo LPS challenge in rats. This increase in IL-10 production occurs at doses of MDMA as low as 1.25 mg/kg, and closely parallels the suppression of TNF- observed in response to MDMA [28] . However the ability of MDMA to suppress LPS-induced TNF- and IL-1 is still evident following immunoneutralization of IL-10, indicating that the suppression of these pro-inflammatory cytokines occurs independent of increased IL-10 production [28] . In addition to suppressing the production pro-inflammatory cytokines, IL-10 also down-regulates expression of the antigen presenting molecule MHC class II, and the co-stimulatory molecule B7 expression on antigen presenting cells, thereby inhibiting antigen presentation producing anergy in the T-cell arm of the immune response [45, 46] . Studies are ongoing in order to determine if the increase in LPS-induced IL-10 production observed following MDMA administration will have a significant impact on the antigen presenting or co-stimulatory capacity of macrophages or dendritic cells. 
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Adaptive immunity
Lymphocytes are the main subset of immune cell that mediate adaptive of specific immune responses. A number of studies indicate that MDMA suppresses lymphocyte function in rats.
The first study to examine the effect of MDMA on immune function demonstrated that quite a high dose of MDMA (20 mg/kg, i.p.) produced a rapid (within 30 min) suppression of Con Ainduced lymphocyte proliferation, and a profound reduction in the total leucocyte count in rats both of which persisted for at least 6 hours following injection [34] . In a subsequent study it was observed that MDMA, its major metabolite MDA, and also the related amphetamine derivative fenfluramine, suppressed circulating lymphocyte numbers, mitogen-stimulated Tcell proliferation and cytokine production, with MDA and fenfluramine being more potent than MDMA with respect to their immunosuppressive actions [32] .
Whilst examining mitogen-stimulated lymphocyte responses gives a useful indication of lymphocyte function, it has the limitation that under normal physiological circumstances the immune system does not encounter mitogens, but rather encounters antigens. Consequently a study was conducted to assess the impact of MDMA administration on an antigen specific immune response to the soluble protein antigen keyhole limpet haemocyanin (KLH) in rats [29] . In this study, KLH-specific immunoglobulin production and KLH-specific cytokine production were assessed as indices of immunocompetence. MDMA did not alter the KLHspecific IgM response. In contrast, MDMA (5 and 10 mg/kg) significantly suppressed KLHspecific IgG production [29] . Therefore whilst MDMA failed to alter the initial generation of the antibody response, it profoundly inhibited antibody class switching from IgM to IgG. Two pathways for the genetic switch from IgM to IgG production were investigated. One pathway decreased KLH-specific splenic IFN-production. Overall, these data indicate that MDMA alters the ability to switch from IgM to IgG 2a production, possibly by reducing production of the TH 1 cytokine IFN-. These data indicated that in addition to the ability of MDMA to suppress lymphocyte response to mitogenic stimuli, that it also suppresses the Th 1 arm of the immune response to an antigenic stimulus.
In vivo effect of MDMA in humans
Over the number of years Pacifici and co-workers have clearly demonstrated that MDMA is a potent immunomodulator in humans [35] [36] [37] [38] [39] . In these studies either placebo or MDMA (75-100 mg) were administered orally to recreational MDMA users in a controlled setting. The effect of ethanol consumption (0.8 mg/kg) on immune function was also assessed, as was the effect of MDMA and ethanol co-administration. These studies were conducted double blind, 
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The first study conducted was a pilot study using four subjects. This study demonstrated that MDMA profoundly suppressed the number of circulating CD4 + T-cells, suppressed mitogen stimulated T-cell proliferation an increased circulating numbers of NK-cells [39] . Although MDMA was shown to increase circulating NK-cell numbers the activity of these NK-cells was not assessed, consequently it is difficult to predict the effect of MDMA on overall NK-cell functionality. In a follow up study the ability of MDMA to reduce the number of circulating Tcells and increase circulating NK-cells was replicated and it was also reported that MDMA and promoted a switch to a Th 2 type cytokine profile and indicated by reduced IFN-and IL-2 production, with an concomitant increase in the Th 2 cytokines IL-4 and IL-6, and the Tregulatory cytokines IL-10 and TGF- 1 [38] . These immunosuppressive effects of MDMA were maximal 3-6 hours following drug administration, and in some cases were evident 24 hours later.
In some instances co-administration of alcohol further enhanced the immunosuppressive effects of MDMA.
In a more recent study Pacifici and colleagues assessed cell-mediated immune responses after administration of two repeated doses of MDMA (100 mg per dose) at 4-hour and 24-hour intervals [37] . habitual users of cannabis with prior experience of cocaine or methamphetamine [36] . As it is well established that cannabis, cocaine and methamphetamine all have significant immunomodulatory properties in their own right [1, 2, 5, 6] , it is impossible to discount the fact that they may have contributed to the immunological changes observed in this experimental group. The second issue pertains to experimental design adopted in the 2 year follow up study.
In this study the control subjects were not tested at 1 and 2 year intervals, thus comparisons were being made using historical data. For these reasons one must be cautious when interpreting these results.
Mechanisms by which MDMA can alter immune function
Direct effects of MDMA on immune cells: Evidence from in vitro studies
The molecular targets for MDMA's action are the transporter (uptake) sites for serotonin and dopamine. Whilst these transporter sites are located predominantly on pre-synaptic serotonergic and dopaminergic neurons respectively, there is now ample evidence the cells of the immune system also express transporter sites for both of these neurotransmitters [see Basal and IL-2 augmented NK cell cytotoxicity were enhanced at concentrations of MDMA between 0.0001 and 0.1 M, however this effect was evident only at one of the three effector:target cell ratios employed. Conversely, IL-2 stimulated NK-cell activity was significantly suppressed by MDMA (10 M), but again this effect was evident only at one of the three effector:target cell ratios employed in the assay. CTL induction was significantly suppressed at a concentration of 100M, but was unaltered at any of the other concentrations used. Finally, LPS-induced macrophage IL-6 or TNF production were not significantly altered by any concentration of MDMA, however there was a slight but statistically non-significant suppression of TNF observed at 10 and 100M MDMA. In summary, the data generated by
House and co-workers (1995) [50] indicates that in vitro exposure to MDMA has variable, and for the most part modest, effects on the immune system depending on the dose employed, and the specific immune parameter under investigation.
In a subsequent study Connor et al., (2000) [31] observed that in vitro exposure of LPSstimulated diluted rat blood to MDMA failed to mimic its ability to suppress the proinflammatory cytokines IL-1 and TNF-following an in vivo LPS challenge; thereby supporting in vitro findings of House et al., (1995) [50] . It was also reported that the ability of MDMA to increase LPS-induced IL-10 production in vivo, was not mimicked by in vitro exposure of LPS-stimulated diluted whole blood cultures to the drug [28] . In addition, the suppressive effect of MDMA on Con A-stimulated lymphocyte proliferation that is observed in vivo cannot be mimicked by in vitro exposure to MDMA (Connor, Unpublished observations).
These data suggest that the potent immunosuppressive actions of MDMA observed following in vivo administration are not due to a direct action of the drug on immune cells, and are likely to be due to the release of endogenous immunomodulatory substances that occurs in response to MDMA. In contrast to these findings, both in vivo and in vitro exposure to MDMA elicit similar suppressive effects on the zymosan-induced oxidative burst in rat neutrophils, indicating that MDMA can elicit a direct effect on neutrophil phagocytosis [27] .
Indirect mechanisms by which MDMA can impact upon the immune system
In addition to having a direct effect on immune cells, it is possible that a drug such as MDMA that alters neurotransmission within the central nervous system (CNS) could alter immunocompetence via a CNS-mediated mechanism. Specifically, it is well established that changes in CNS neurotransmitter function can alter immunity via changes in endocrine output and sympathetic nervous system activity [51, 52] . MDMA stimulates the release of the neurotransmitters serotonin and dopamine in the central nervous system [17, 18] , and produces consequential downstream activation of peripheral immunomodulatory pathways such as the hypothalamic pituitary adrenal axis and the sympathetic nervous system [23, 53] . Therefore when addressing the underlying physiological mechanisms that mediate the immunosuppressive effects of MDMA, it is necessary to consider central neurotransmitters that drive downstream responses, and also peripheral neurotransmitters and hormones that are the ultimate mediators impacting on immune cells.
Central mediators of MDMA-induced immunosuppression
As the predominant neurochemical action of MDMA is to release serotonin within the CNS, it is logical to assume that central serotonin release may mediate the actions of MDMA on the immune system. In this regard it was demonstrated that the related amphetamine compound fenfluramine that is a selective releaser of serotonin produced qualitatively similar suppressive effects to MDMA on a number of immunological measures in a rats [32, 54] . For instance fenfluramine suppressed circulating lymphocyte numbers, suppressed T-lymphocyte proliferation and cytokine production [32] , and also suppressed production of the proinflammatory cytokines IL-1and TNF-in response to an in vivo LPS challenge [54] . It was also of interest that fenfluramine was more potent than MDMA at inducing serotonergic changes, and also at provoking immunosuppressive effects [32] . All of this data pointed towards serotonin release as a mediator of the immunosuppressive effects of MDMA in rats. 
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In order to evaluate the role of serotonin in MDMA-induced immunosuppression, two pharmacological strategies that inhibit MDMA-induced serotonin release were employed.
Firstly, the selective serotonin reuptake inhibitor paroxetine was used to prevent MDMA from entering serotonergic neurons, thereby preventing MDMA-induced serotonin release [30] . In the second study rats were pre-treated with the tryptophan hydroxylase inhibitor p- possibly by its ability to increase central serotonin concentrations [30] . The treatment regimen of pCPA used caused in excess of a 90% depletion of brain serotonin concentrations. However, the suppressive effects of MDMA on LPS-induced IL-1 and TNF-were equivalent in both saline and pCPA-treated groups. In all these data indicated that the immunosuppressive effects of MDMA occur by a mechanism(s) independent of serotonin release. In a similar manner it was observed that the suppressive effect of fenfluramine (10 mg/kg) on LPS-induced IL-1 and TNF- production were not blocked by pre-treatment with either paroxetine or pCPA [55] .
However in a later study using much lower doses of fenfluramine (1.25 and 2.5 mg/kg), it was observed that the suppressive effect of fenfluramine on LPS-induced IL-1production was blocked by pre-treatment with pCPA, indicating that it was indeed a serotonin-dependent event [56] . In a similar fashion it is also possible that serotonin may contribute to the In contrast to the studies outlined above that failed to elucidate a role for serotonin in MDMAinduced immunosuppression in rats [30] , a recent study in humans demonstrated that pretreatment with the serotonin reuptake inhibitor paroxetine could block some of the immunosuppressive effects of MDMA. Specifically, paroxetine pre-treatment partially inhibited that ability of MDMA to suppress circulating CD4+ T helper cell numbers, and to increase circulating NK-cell numbers [35] . In addition, paroxetine totally abolished the suppressive effect of MDMA on lymphocyte proliferation and IL-2 production induced by the T-cell mitogens Con A and PHA, and blocked the ability of MDMA to enhance PHAstimulated production of the anti-inflammatory cytokines IL-10 and TGF-. In all, these data support a role for serotonin release in mediating the suppressive effect of MDMA on human Tcell function.
In addition to the potent serotonin-releasing properties of MDMA, it is also well established that MDMA releases dopamine within the CNS, although with less potency [17, 18] . Thus, it is possible that dopamine release may play a role in the immunosuppressive effects of MDMA. In this regard, it was previously demonstrated that both d-amphetamine and methamphetamine; two psychostimulants that are structurally related to MDMA (see Figure 1 ) and are potent dopamine releasers, elicit immunosuppressive effects in rodents [6, 57, 58] . Future studies will evaluate the role of dopamine in MDMA-induced immunosuppression.
Does behavioural stimulation play a role in the immunosuppressive effect of MDMA ?
MDMA provokes a variety of euphoric effects in humans and behavioural hyperactivity in laboratory animals [see 15]. It is of interest that previous studies demonstrated that depletion of serotonin concentrations with p-chlorophenylalanine or blockade of serotonin release by pretreatment with SSRI's attenuate the locomotor stimulant effect of MDMA in rats [19] .
Therefore whilst pretreatment with paroxetine or p-chlorophenylalanine attenuates the behavioural effects of MDMA, the immunosuppressive effects (at least on pro-inflammatory cytokine production) still persist, indicating a dissociation between the behavioural and immunosuppressive effects of MDMA [30] . In addition, the fact that the non-psychostimulant amphetamine derivative fenfluramine elicits similar immunosuppressive effects to MDMA [32, 54, 56] , supports the view that the psychoactive and immunosuppressive properties of substituted amphetamines in rats are not necessarily linked.
A previous study conduced in humans reported that treatment with the SSRI citalopram blocked the positive mood, extraversion and self-confidence induced by MDMA [21] . In addition, some of the immunosuppressive actions of MDMA in humans are blocked by serotonin transporter blockade with the related SSRI paroxetine [35] . However, despite these co-incidental effects, the exact role that the euphoric effect of MDMA plays in its ability to induce immunosuppression in humans is not clear. 
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Does hyperthermia play a role in the immunosuppressive effect of MDMA ?
Since MDMA is known to induce hyperthermia it is pertinent to address the possibility that the ability of MDMA to alter body temperature could contribute to its immunomodulatory effects.
However, based on evidence from the published literature it appears unlikely that MDMAinduced hyperthermia plays a significant role in its immunomodulatory effects. For instance, the ability of MDMA to promote an immunosuppressive cytokine phenotype (reduced TNF- and increased IL-10), and a suppression of lymphocyte proliferation are observed at doses as low as 1.25 mg/kg [28, 33] ; a dose that does not alter body temperature [59] . In addition, whilst both MDMA and the related amphetamine fenfluramine provoke similar immunosuppressive responses in rats, they provoke opposite thermal responses with fenfluramine eliciting a hypothermic response [60] , and MDMA eliciting a hyperthermic response [23] . It is well established that MDMA activates both the hypothalamic pituitary adrenal axis and sympathetic nervous system [23, 33, 53] , and that the end products of these axes namely glucocorticoids and catecholamines have immunosuppressive properties [61, 62] . Therefore it was plausible to suggest that MDMA could elicit its immunosuppressive actions by increasing the release of these endogenous negative immunoregulators. Consistent with this hypothesis, it was demonstrated that the increase in IL-10 induced by MDMA could be blocked by pretreatment with the -adrenoceptor antagonists propranolol and nadolol, indicating that the MDMA-induced enhancement of IL-10 production was mediated by -adrenoceptor activation, presumably in response to MDMA-induced catecholamine release [28] . In contrast, the suppression of pro-inflammatory cytokines TNF- and IL-1 induced by MDMA occurred independent of -adrenoceptor activation [28] . However the possibility still exists that catecholamines may mediate the suppression of pro-inflammatory cytokines induced by MDMA by acting on other adrenoceptor subtypes such as the  1 -adrenoceptor.
With respect to the role of glucocorticoids in MDMA-induced immunosuppression, it was observed that pre-treatment of rats with the glucocorticoid receptor antagonist mifepristone failed to block the suppressive effect of MDMA on LPS-induced IL-1 and TNF- production (Connor, unpublished data) . Moreover in a recent study it was observed that adrenalectomy failed to block the ability of MDMA to suppress TNF-and increase IL-10 production [28] .
These data clearly demonstrate that glucocorticoids do not mediate the ability of MDMA to promote an immunosuppressive cytokine phenotype in rats. However further studies are Whilst it has been demonstrated that MDMA activates the hypothalamic pituitary adrenal axis and sympathetic nervous system in humans [39, 53] , the effect of glucocoticoid receptor antagonists/synthesis inhibitors or adrenoceptor antagonists have not been examined in human studies.
A role for peripheral serotonin or dopamine in the immunosuppressive actions of MDMA ?
Serotonin
Immune cells have ample opportunity to be exposed to serotonin that is released from platelets in the periphery [see 48]. In addition to platelet-derived serotonin, it was previously suggested that sympathetic nerve terminals in lymphoid tissues take up serotonin, which can be released upon later stimulation of these nerves [49] . Moreover, it is well established that serotonin receptors are present on a variety of immune cells [see 48, 49] , and that serotonin has immunomodulatory properties, with some studies indicating that it enhances, and others In addition, noradrenergic sympathetic fibres in the spleen can take up circulating dopamine particularly during stress, which may then be released on sympathetic activation, and act upon 
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MDMA abuse -A stressor on the immune system As many of the physiological changes elicited by MDMA closely resemble those induced by psychological or physical stress, it is suggested that exposure to MDMA could be regarded as a "chemical stressor" on the immune system. Exposure to stress is known to provoke similar immunological changes in both in laboratory animals and in man to those induced by MDMA.
For instance, acute stress promotes an immunosuppressive cytokine phenotype in response to LPS [72, 73] . Stress also suppresses lymphocyte proliferation and promotes a Th2 type cytokine response [74] [75] [76] [77] [78] [79] , and increases circulating NK-cell numbers [79] [80] [81] . rise to concern considering the important role that NK-cells play in cell-mediated immunity, and more particularly in tumour surveillance [84, 85] . Having all this said, it is difficult to predict the impact of MDMA-induced immunosuppression on disease susceptibility, as we don't know what degree of functional reserve is present within the immune system, and also as there are no data available regarding the impact of MDMA administration on host resistance in infection models. However, it was previously demonstrated that administration of damphetamine the parent compound of MDMA reduced host resistance to infection by influenza A virus and the bacteria Listeria monocytogenes [11, 57] . Nonetheless, studies examining susceptibility to bacterial/viral infections are required in order to determine as to whether impairments in innate and adaptive immunity induced by MDMA have a major impact on infectivity and disease progression.
There are very few studies in the clinical literature that have examined the incidence of infections in MDMA abusers. However one recent report presented the results of a survey of 282 Ecstasy users that participated in a WWW study [86] . The sample was comprised of 109 novice users (1-9 occasions), 136 moderate users (10-99 occasions), and 36 heavy users (+100 occasions). In this study yes/no responses were recorded to a series of questions covering problems experienced when drug-free which were attributed by the respondents to their Ecstasy use. In this survey, infections were cited as one of the problems that were significantly associated with the extent of Ecstasy use [86] . In addition, there have been cases where MDMA abuse in humans closely preceded the development of meningococcal meningitis [87] .
It is also possible that both the environment in which MDMA is consumed, and/or the psychoactive effects that MDMA induces, could synergise with the immunosuppressive effects 
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of the drug, to result in increased susceptibility to infectious disease. For instance MDMA use has traditionally been associated with the rave dance club scene; a crowded and environment where teenagers congregate. Such an environment is optimal for transmitting airborne infection between individuals. In addition, the results of a recent study indicated that MDMA abuse was strongly and significantly associated with high-risk sexual behaviors (unprotected anal intercourse) in a population of gay/bisexual men sampled from three New York dance clubs [88] . Thus when one combines such environmental factors with the immunosuppressive effect of MDMA, it is reasonable to suggest that MDMA users may have a higher risk of developing infectious disease in comparison to drug-free subjects.
Conclusions
Research conducted over the last five years has clearly demonstrated that administration of MDMA to both animals and humans has profound immunosuppressive effects; a property that it shares with other drugs of abuse [1] [2] [3] [4] [5] [6] . For the most part the immunosuppressive effects of MDMA are not due to a direct action of the drug on immune cells, but rather due to the release of endogenous immunomodulatory substances, and it is suggested that exposure to MDMA could be regarded as a "chemical stressor" on the immune system. Further studies are required in order to elucidate the central and peripheral mediators of MDMA-induced immunosuppression. In addition, assessment of the effect of MDMA in pre-clinical host resistance models, and further clinical research is required before any definitive statement can be made on the propensity of MDMA-induced immunosuppression to translate into increased disease susceptibility.
